Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3183-3189

  Holsinger, F Christopher ^a   Doan, Dao D ^a   Jasser, Samar A ^a   Swan, Eric A ^a   Greenberg, Jayson S ^b   Schiff, Bradley A ^a   Bekele, B Nebiyou ^a   Younes, Maher N ^a   Bucana, Corazon D ^a   Fidler, Isaiah J ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PLACEBO; PROPIDIUM IODIDE; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASSAY; AUTOPHOSPHORYLATION; AUTOPSY; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MOUTH CANCER; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TONGUE; TONGUE TUMOR; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; LIGANDS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MOUTH NEOPLASMS; NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROPIDIUM; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TONGUE; TONGUE NEOPLASMS; TYROSINE;

EID: 12444260696     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Clark, J. W. Targeted therapy. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed., pp. 891-910. Philadelphia: Lippincott Williams & Wilkins, 2001.
2. Stephenson, J. Researchers optimistic about sea change in cancer treatment. J. Am. Med. Assoc., 285: 2841-2842, 2001.
3. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
4. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke M., Silberman S., and Nielsen O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet, 358: 1421-1423, 2001.
5. Sturgis, E. M., Sacks, P. G., Masui, H., Mendelsohn, J., and Schantz, S. P. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol. Head Neck Surg., 111: 633-643, 1994.
6. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
7. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., and Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18: 904-914, 2000.
8. Busse, D., Yakes, F. M., Lenferink A. E., and Arteaga, C. L. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin. Oncol., 28: 47-55, 2001.
9. Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., and Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev., 21: 499-512, 2001.
10. Solorzano, C. C., Baker, C. H., Tsan, R., Traxler, P., Cohen, P., Buchdunger, E., Killion, J. J., and Fidler, I. J. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res., 7: 2563-2572, 2001.
11. Papadimitrakopoulou, V. A., Murren, J. R., Fidler, I. J., Bucana, C. D., Sizer, K., Cohen, P., Ravera, C., and Abbruzzese, J. L. A Phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Clin. Cancer Res., 7: 3708s, 2001.
12. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R. I., and Baselga, J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol., 20: 110-124, 2002.
13. Myers, J. N., Holsinger, F. C., Bekele, B. N., Li, E., Jasser, S. A., Killion, J. J., and Fidler, I. J. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch. Otolaryngol. Head Neck Surg., 128: 875-879, 2002.
14. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
15. Bonner, J. A., Raisch, K. P., Trummell, H. Q., Robert, F., Meredith, R. F., Spencer, S. A., Buchsbaum, D. J., Saleh, M. N., Stackhouse, M. A., LoBuglio, A. F., Peters, G. E., Carroll, W. R., and Waksal, H. W. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol., 18: 47S-53S, 2000.
16. Ciardiello, F., Caputo, R., Borriello, G., Del Bufalo, D., Biroccio, A., Zupi, G., Bianco, A. R., and Tortora, G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer, 98: 463-469, 2002.
17. Bianco, C., Tortora, G., Bianco, R., Caputo, R., Veneziani, B. M., Damiano, V., Troiani, T., Fontanini, G., Raben, D., Pepe, S., Bianco, A. R., and Ciardiello, F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res., 8: 3250-3258, 2002.
18. Swan, E. A., Jasser, S. A., Holsinger, F. C., Doan, D. D., Bucana, C. D., and Myers, J. N. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol., in press, 2003.
19. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
20. Myers, J. N., Holsinger, F. C., Jasser, S. A., Bekele, B. N., and Fidler, I. J. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin. Cancer Res., 8: 293-298, 2002.
21. Traxler, P., Buchdunger, E., Furet, P., Gschwind, H-P., Ho, P., Mett, H., O'Reilly, T., Pfaar, U., and Thomas, H. Preclinical profile of PKI166: a novel and potent EGF-R tyrosine kinase inhibitor for clinical development. Clin. Cancer Res., 5: 3750s, 1999.
22. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
23. Tedjarati, S., Baker, C. H., Apte, S., Huang, S., Wolf, J. K., Killion, J. J., and Fidler, I. J. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon α combined with paclitaxel. Clin. Cancer Res., 8: 2413-2422, 2002.
24. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.
25. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90: 9552-9556, 1993.
26. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Mahoney, M. E., and Huang, Y. Taxol induces intemucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (Baltimore), 7: 563-568, 1993.
27. Sorger, P. K., Dobles, M., Tournebize, R., and Hyman, A. A. Coupling cell division and cell death to microtubule dynamics. Curr. Opin. Cell Biol., 9: 807-814, 1997.
28. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
29. Moos, P. J., and Fitzpatrick, F. A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ., 9: 687-697, 1998.
30. Torres, K., and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58: 3620-3626, 1998.
31. Wang, T. H., Wang, H. S., and Soong, Y. K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer (Phila.), 88: 2619-2628, 2000.
32. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81: 727-736, 1995.
33. Page, C., Lin, H. J., Jin, Y., Castle, V. P., Nunez, G., Huang, M., and Lin, J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res., 20: 407-416, 2000.
34. Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., and Testa, J. R. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res., 60: 5390-5394, 2000.
35. Okano, J., and Rustgi, A. K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J. Biol. Chem., 276: 19555-19564, 2001.
36. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.